The FDA delayed by three months its approval decision on Onglyza, an experimental diabetes drug from AstraZeneca and Bristol-Myers Squibb. The agency said it needs more time to review Onglyza, although a spokesman for Bristol-Myers said he was not aware of any request from the agency for additional data on the product.

Full Story:

Related Summaries